3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
16
Thoracic
3
Lymphoid
3
Gastrointestinal
3
Breast
3
Gynecologic
2
Genitourinary
2
Endocrine
2
Dermatologic
2
CNS
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Head & Neck
1
Conditions
Neuroendocrine Tumors
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms, Unknown Primary
1
Interventions
Fluorodeoxyglucose F18
2
tivozanib
1
tislelizumab
1
surufatinib
1
romidepsin
1
repotrectinib
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
atezolizumab
1
alectinib
1
Quality of Life
1
Patient Reported Outcome Measures
1
PM 01183
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lactones
1
Irinotecan
1
Interleukin-2
1
Immunotherapy
1
FAPI-46
1
Drug Therapy
1
Depsipeptides
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Drug Therapy
×
NET
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled